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ABSTRACT: Inhibition of protein kinases using ATP-competitive compounds is an important strategy in drug discovery. In
contrast, the allosteric regulation of kinases through the disruption of protein−protein interactions has not been widely adopted,
despite the potential for selective targeting. Aurora-A kinase regulates mitotic entry and mitotic spindle assembly and is a
promising target for anticancer therapy. The microtubule-associated protein TPX2 activates Aurora-A through binding to two
sites. Aurora-A recognition is mediated by two motifs within the ﬁrst 43 residues of TPX2, connected by a ﬂexible linker. To
characterize the contributions of these three structural elements, we prepared a series of TPX2 proteomimetics and investigated
their binding aﬃnity for Aurora-A using isothermal titration calorimetry. A novel stapled TPX2 peptide was developed that has
improved binding aﬃnity for Aurora-A and mimics the function of TPX2 in activating Aurora-A’s autophosphorylation. We
conclude that the helical region of TPX2 folds upon binding Aurora-A, and that stabilization of this helix does not compromise
Aurora-A activation. This study demonstrates that the preparation of these proteomimetics using modern synthesis methods is
feasible and their biochemical evaluation demonstrates the power of proteomimetics as tool compounds for investigating PPIs
involving intrinsically disordered regions of proteins.
The mitotic spindle is a molecular machine built frommicrotubules and associated proteins that carries out the
segregation of chromosomes during cell division. Assembly of
the mitotic spindle is regulated by reversible phosphorylation of
microtubule-associated proteins by Aurora-A and other protein
kinases.1,2 In humans, there are two other members of the
Aurora family (Aurora-B and Aurora-C), all members of which
are serine−threonine protein kinases with very similar catalytic
domains and highly variable N-terminal regions. Aurora-A is
concentrated at the poles of the mitotic spindle and along
microtubules and functions in centrosome maturation, spindle
assembly, maintenance of spindle bipolarity, and mitotic
checkpoint control.3,4
The catalytic activity of Aurora-A is stimulated by
phosphorylation and interactions with other proteins.5−7
Many activating binding partners have been identiﬁed; however
the interplay between them is unclear. The best characterized of
these pathways, and arguably the most important for
establishing high Aurora-A kinase activity in early mitosis,
involves the microtubule-associated protein TPX2 (Targeting
Protein for Xenopus kinesin-like protein 2).2,8−11 Chromatin
signals to the spindle assembly machinery using small GTPase
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RAs-related Nuclear protein (RAN), highly concentrated
around the chromatin. RAN, in turn, releases central spindle
assembly factors, including TPX2 from transport factors
(importin α/β) in the vicinity of chromatin.12 TPX2 then
localizes, binds to, and activates the autophosphorylation of
Aurora-A on Thr288.13 Aurora-A promotes spindle assembly,
organization, and stabilization via phosphorylation of micro-
tubule (MT) related proteins such as transforming acidic
coiled-coil-containing protein 3 (TACC3). TACC3 is also an
activator of Aurora-A, and this mechanism serves to ﬁne-tune
the rate of spindle assembly through the regulation of its
complexes with ch-TOG and clathrin.14
The crystal structure of the Aurora-A catalytic domain
(aa122−403) phosphorylated on Thr287 and Thr288 in
complex with the minimal domain of TPX2 (aa1−43), which
is suﬃcient to bind and activate Aurora-A in vitro, shows how
TPX2 stabilizes the active conformation of the kinase (Figure
1A).15 TPX2 binds to Aurora-A with two separate segments:
the upstream stretch (residues Ser7TPX2−Ser21TPX2), which is in
an extended conformation (red), binds to Aurora-A’s N-
terminal lobe and stabilizes the position of the C-helix; the
downstream stretch (residues Asn30TPX2−Asn43TPX2), which is
in an α-helical conformation (blue), binds between the N- and
C-terminal lobes and stabilizes the activation loop to form a
platform for substrate binding (Figure 1B). The region (pink)
between these segments does not appear in the crystal
structure, and the contribution of this region of TPX2 to the
interaction with Aurora-A, if any, is unknown (Figure 1C).
The insertion of two aromatic side chains on the helix of
TPX2 (Trp34, Phe35) into a pocket between the N- and C-
lobes of Aurora-A locks the activation loop into a conformation
in which the side chain of phospho-Thr288AUR is buried. This
stabilizes Aurora-A to dephosphorylation by protein phospha-
tase 1 (PP1) and increases kinase activity further. In the
absence of TPX2, the activation loop is dynamic and, unusually
for a protein kinase, activating phosphorylation is not suﬃcient
to stabilize the conformation of the activation loop. Indeed, a
point mutation within the helical region (W34A) fails to
protect Aurora-A from dephosphorylation by PP1.16 However,
the helix does not appear to play a major role in the ability of
TPX2 to stimulate the autophosphorylation of Aurora-A, and
the helix was unresolved in the crystal structure of
unphosphorylated Aurora-A catalytic in complex with TPX2
(aa1−43).17 This raises the question of whether the helix is
present in TPX2 alone, or if it forms upon binding to
phosphorylated Aurora-A.
Regulation of PPIs is a signiﬁcant challenge in chemical
biology and medicinal chemistry. A diverse array of
peptidomimetic molecular scaﬀolds that mimic peptide
secondary structures (e.g., α-helix, turn, and β-sheet) and
have improved physiochemical properties have been developed
to disrupt PPIs.18 A peptidomimetic can be deﬁned as a
compound that mimics a short peptide with a single secondary
structure binding motif. Compounds that mimic the structure
and function of extended regions of protein surfaces
incorporating more than one secondary structure or binding
epitope are proteomimetics.19
The structure of Aurora-A/TPX2 has provided key insights
into the nature of the protein−protein interaction and
mechanism of activation of this essential kinase. However,
many aspects of this dynamic complex have yet to be resolved.
What is the role of the TPX2 linker sequence not observed in
the crystal structure? Does the helical region of TPX2 form
upon binding to Aurora-A, and if so, can the entropic penalty of
helix formation be partially overcome using a helix conforma-
tional constraint? To address these questions, we have designed
Figure 1. (A) X-ray crystal structure of the Aurora-A−TPX2 complex (PDB 1OL5).15 TPX2 nonstructured binding motif (red) and TPX2 α-helix
(blue). (B) X-ray crystal structure of TPX2 minimal binding domain complex. (C) Sequence of the TPX2 N-terminal domain. TPX2 upstream
stretch (extended sequence (red)), TPX2 downstream stretch (α-helix (blue)), and the ﬂexible linker (pink).
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and synthesized a series of proteomimetic chemical probes and
investigated their binding aﬃnity to Aurora-A. We generated a
hydrocarbon-stapled TPX2 proteomimetic that recreates the
activity of native TPX2, but with higher aﬃnity binding, and
determined the crystal structure in complex with Aurora-A.
■ RESULTS AND DISCUSSION
TPX2 interacts with Aurora-A through two separate motifs: an
upstream stretch in an extended conformation (residues
Ser7TPX2−Ser21TPX2) and a downstream stretch in an α-helical
conformation (residues Asn30TPX2−Asn43TPX2). The middle
section of TPX2 that links these two motifs (residues
Leu22TPX2−Gln29TPX2) is not resolved in the crystal structure
and so is believed to be ﬂexible and disordered.
To investigate whether the side-chain residues of this linker
region contribute to the binding aﬃnity of Aurora-A/TPX2
PPI, an analogue was prepared incorporating a polyglycine
chain in place of the linker domain (Table 1). Although
recombinant expression would have provided the appropriate
molecule, we require the ability to incorporate non-native
amino acids going forward, and so chose to prepare the peptide
synthetically. Peptides of greater than 20 residues in length are
known to be diﬃcult to synthesize due to problems with on-
resin aggregation resulting in deletion sequences and/or
complete failure of the synthesis.20 Microwave-assisted solid-
phase peptide synthesis overcomes this problem simply
through heating the coupling and deprotection reactions.21
Table 1. Sequences of TPX2 Proteomimetics Prepared and Used in Binding Studies
Figure 2. Representative ITC traces of the binding between Aurora-A and diﬀerent TPX2 variants: native linker 2 (A), Gly5 linker 4 (B), Gly8 linker
3 (C), Gly11 linker 5 (D).
Table 2. Thermodynamic Parameters for Binding of Diﬀerent TPX2 Variants to Aurora-A As Determined by ITCa
TPX2 variant ID Residues Ka (10
3 M−1] ΔH (kcal mol−1) TΔS (kcal mol−1) ΔG (kcal mol−1) Kd (μM)
Native linker 2 7−43 468.67 ± 55.81 −23.00 ± 0.83 −15.37 −7.63 2.16 ± 0.28
Gly5 linker 4 7−43b 377.00 ± 52.31 −18.38 ± 3.74 −10.89 −7.49 2.73 + 0.38
Gly8 linker 3 7−43 410.33 ± 22.03 −18.57 ± 1.58 −11.03 −7.54 2.46 ± 0.13
Gly11 linker 5 7−43c 68.20 ± 7.00 −15.92 ± 1.17 −9.43 −6.49 14.82 ± 1.52
Stapled helix 8 30−43d no binding detected
Native helix 9 30−43 no binding detected
Extended motif 7 7−25 no binding detected
Native TPX2 1 1−43 308.33 ± 79.98 −26.19 ± 2.88 −18.81 −7.38 3.54 ± 1.15
Stapled TPX2 10 l−43d 5505.00 ± 49.50 −42.57 ± 1.09 −33.55 −9.02 0.18 ± 0.00
aKa, binding constant; ΔH and ΔS, enthalpic and entropic terms; T = 293 K; AG, Gibbs’ free energy change; Kd, dissociation constant. All
experiments were performed at least in duplicate other than for Gly11 linker, which was performed once. Values quoted were given by Origin
software upon curve ﬁtting, and errors are the standard deviation between replicate values or the errors given by Origin curve ﬁtting for Gly11.
bThis
peptide contains native residues 7−21 and 30−43, with ﬁve glycine residues linking the two domains. cThis peptide contains native residues 7−21
and 30−43, with 11 glycine residues linking the two domains. dGlu37 and Leu41 replaced by unnatural α-methyl, α-alkenyl amino acid “S5.”
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Using this method and a Fmoc/tBu protection strategy, the
TPX2 proteomimetics were prepared in satisfactory yields.
Quantitative analysis of binding aﬃnity (Kd) of the synthetic
analogues, compared with the native TPX2 sequence, to the
catalytic domain of Aurora-A (122−403) was achieved using
isothermal titration calorimetry (ITC; Figure 2). The measured
Kd’s of the interaction between Aurora-A and synthetic native
peptides (1−43) 1 and (7−43) 2 were similar to the published
value (Table 1).17 TPX2 analogue 3 incorporates an eight
residue (and therefore equivalent length) polyglycine linker
sequence that maintained binding aﬃnity relative to the native
sequence 2, which suggests that the side-chain functionality of
the amino acids in this linker region are not required for
binding to Aurora-A. The Xenopus and puﬀer ﬁsh homologues
of TPX2 incorporate a shorter linker sequence with three
residues Gly26TPX2−Thr28TPX2 missing.15 A synthetic TPX2
analogue 4 with a shorter, ﬁve-residue polyglycine linker that is
comparable to these other isoforms was prepared to investigate
whether binding to Aurora-A would be compromised. This
shorter analogue 4 gave comparable binding aﬃnity to the
native sequence 2. To further probe the structural requirements
of this linker, an analogue incorporating an 11-residue
polyglycine linker 5 was prepared. An 8-fold weaker binding
aﬃnity was observed for this longer analogue, which suggests
that shorter but not longer linkers are tolerated. This would be
expected based on the entropic penalty of folding the
conformationally more ﬂexible longer sequence 5 versus the
shorter peptide sequence 4.
To probe the structural requirements of the extended region
of TPX2 Ser7TPX2−Ser21TPX2 region, we synthesized a TPX2
peptide analogue 6 of this domain (see Table 2). Unfortu-
nately, this motif proved to be insoluble in aqueous solution
and not amendable to use in ITC experiments. To overcome
this solubility issue, we chose to extend the sequence by four
residues to include charged/polar residues Leu22TPX2−
Glu25TPX2. This analogue 7 demonstrated good aqueous
solubility; however, it did not bind to Aurora-A with signiﬁcant
aﬃnity.
Stapled peptides have recently come of age as tool
compounds to disrupt PPIs mediated by an α-helix. First
proposed by Grubbs and Blackwell22 and then developed by
Verdine and co-workers,23 these constrained peptides have
been designed to target a range of diﬀerent biologically relevant
PPIs including the AKAP complex.24−27 These peptidomi-
metics have also been demonstrated to overcome a number of
the physicochemical problems associated with peptides such as
poor bioavailability, limited protease stability, and a lack of
membrane permeability.28−30
The downstream TPX2 domain forms an α-helical
conformation (residues Asp30TPX2−Asp43TPX2) in the Aurora-
A/TPX2 crystal structure and makes a series of key interactions
that contribute to binding aﬃnity. In solution, TPX2 30−43
adopts a random coil, and the helix must therefore fold upon
binding to Aurora-A (Figure 3). Incorporating a conformational
constraint into the peptide sequence to induce an α-helix in this
region of TPX2 should therefore overcome some of the
entropic penalty of folding and provide a proteomimetic with
increased binding aﬃnity.
We initially designed a stapled peptide 8 based only on the
helix region (Asp30TPX2−Asn43TPX2). Examination of the
Aurora-A/TPX2 crystal structure provides the structural
information required to select two residues on the solvent-
facing side of the helix that are not involved in the binding
event. Careful design of the staple was required because we
predicted that stabilization of the helix C-terminal loop at
residues Trp34TPX2−Phe35TPX2 would result in a steric clash
with Aurora-A. As such, the i and i + 4 residues Glu37TPX2 and
Leu41TPX2 were replaced with an α-methyl, α-alkenyl amino
acid (S5) in order to conformationally constrain the N-terminal
loop of the helix. Macrocyclization was accomplished on solid
support using ring-closing oleﬁn metathesis.
Circular dichroism spectroscopy conﬁrmed that the native
TPX2 (30−43) peptide 9 is a random coil with no deﬁned
secondary structure but that the stapled TPX2 (30−43) peptide
8 is helical (Figure 4). Native TPX2 peptide (30−43) 9, lacking
the constraint, has a negative band at 199 nm, characteristic of
random coil.31 The stapled peptide 8 has negative bands at 208
and 222 nm, characteristic of an α-helical conformation.
However, neither the stapled peptide 8 nor corresponding
native peptide 9 demonstrated signiﬁcant binding aﬃnity for
Aurora-A. This suggests that the TPX2 helix region alone does
not bind signiﬁcantly to Aurora-A but requires the upstream-
extended sequence motif (Ser7TPX2−Ser21TPX2) to enhance
binding.
With this knowledge, we decided to investigate if a full length
stapled TPX2 peptide would bind with increased aﬃnity when
compared to the native sequence. The synthesis of this TPX2
stapled analogue 10 was achieved using microwave assisted
solid phase synthesis and pseudoprolines to prevent on resin
aggregation of the peptide (see Supporting Information). In
our initial attempt to synthesize this peptide, we also observed
aspartimide formation as a major side reaction. This was
overcome by adding organic acid (e.g., oxyma) to the
deprotection solution, generating piperidinium ion, which
suppresses aspartimide formation.32
Gratifyingly, the stapled TPX2 peptide 10 was observed by
ITC to bind with higher aﬃnity than the corresponding
unconstrained native peptide 1 (Figure 4A). The thermody-
namic parameters determined from ITC measurements of
native TPX2 peptide 1 and stapled TXP2 peptide 10 indicate
that the Gibbs free energy of binding is predominantly driven in
both cases by a favorable enthalpic term (ΔH = −26.19 and
−42.57 kcal/mol). This suggests that the conformationally
constrained peptide 10 makes more favorable interactions with
Aurora-A than the native peptide (vide inf ra).
Figure 3. CD spectra of stapled TPX2 helix (30−43) peptide 8 and
native TPX2 (30−43) peptide 9.
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Interestingly, the entropic term for the constrained peptide
10 is more unfavorable when compared to the native TPX2
peptide 1 (TΔS = −18.81 to −33.55 kcal/mol). Two major
terms contribute to the entropy of binding, the conformational
entropy change, and the desolvation entropy change.33 We have
demonstrated that the entropic penalty of folding the helix
Figure 4. (A) Representative ITC traces of the binding between Aurora-A and diﬀerent TPX2 variants; native 1−43 (1), stapled 1−43 (10). (B)
Comparison of the eﬀect of recombinant TPX2 1−43 and stapled TPX2 1−43 (10; 20 μM) on the autophosphorylation of Aurora-A (2.5 μM) on
Thr288 through ATP (160 μM) turnover. Samples were separated by SDS-PAGE and analyzed by Coomassie staining (top) and their
phosphorylation state probed by Western blot using an antibody speciﬁc for phosphorylated Thr288 (Cell Signaling; bottom). Aurora-A prepared in
the absence of phosphatase, which is fully phosphorylated on Thr-288, is included as a positive control in the ﬁrst lane and labeled “Phosphorylated.”
Figure 5. (A) Aurora-A (gray) in complex with stapled TPX2 protein 10 (cyan; PDB: 5LXM). The hydrocarbon staple is shown as sticks with the
rest of TPX2 shown as a cartoon. The ﬂexible region linking the extended sequence and α-helical domains of TPX2 (not visible in the crystal
structure) is represented as a dark blue dashed line. (B) Zoomed in view of the hydrocarbon staple with the ﬁnal 2mFo-DFc electron density map
shown as wire-mesh contoured at 1.0 σ. (C) Side view of the TPX2 helix showing the distance of the staple from the Aurora-A surface. The closest
residue, His187, is 9.1 Å from the staple. Trp34 and Phe35 of TPX2, known to make crucial interaction with Aurora-A residues, are shown as sticks.
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region can be overcome by the conformational constraint.
However, the constraint may restrict the peptide from adopting
the correct conformation for binding, which may be subtly
diﬀerent from the conformation of the unbound constrained
peptide. These data can also be rationalized by considering the
positive entropic contribution made by desolvation of water
molecules coordinated to the native TPX2 peptide 1 backbone
amide functionality. When constrained, this amide functionality
is involved in the intramolecular H-bonding network of the α-
helix and so is not available to coordinate water.
TPX2 stimulates the autophosphorylation of Aurora-A on
Thr288, an event that can be detected using a site-speciﬁc
antibody. We conﬁrmed that the TPX2 1−43 proteomimetic
10 retained the ability to induce Aurora-A phosphorylation,
similar to the recombinant, native 1−43 peptide (Figure 4B).
Encouraged by the relatively high binding aﬃnity value found
between the stapled TPX2 peptide and Aurora-A, we
crystallized and solved the structure of the complex (PDB:
5LXM, Figure 5A). Electron density was visible for four more
TPX2 residues in our model than in that of native TPX2, Ser6
at the N-terminus of the peptide, Leu22 at the start of the
ﬂexible linker region, and Thr28 and Gln29 directly after the
linker, suggesting a lower degree of ﬂexibility in the stapled
peptide compared to native TPX2. To model the hydrocarbon
staple, we exchanged residues Glu37 and Leu41 for the
unnatural amino acid 2-methyl-L-norleucine (PDB: MK8) and
formed the double bond between the two alkyl chains using
geometric and planar restraints (Figure 5B).
As with the previous structures of the Aurora-A/TPX2
complex, the interactions of the other two regions of TPX2
with Aurora-A are well-resolved. The region from Ser7TPX2 to
Ser21TPX2 adopts an extended conformation characterized by
minimal intramolecular contacts and extensive main and side
chain interactions with Aurora-A. Residues Tyr8TPX2,
Tyr10TPX2, and Ala12TPX2 sit tightly in hydrophobic pockets
between the β-sheetAUR, helix αBAUR, and helix αCAUR. Whereas
segment Phe16TPX2−Phe19TPX2 tightly nestle in an adjacent
hydrophobic pocket of Aurora-A. Phe16TPX2 also forms a
cation−π interaction with Arg126AUR. Aromatic residues
Trp34TPX2 and Phe35TPX2 in the helical region of TPX2
interact with His187AUR and His280AUR. Ala39TPX2 interacts
with the activation segment at Pro282AUR (Figure 5C).
The staple itself clearly does not interact with the surface of
Aurora-A (Figure 5C). The nearest Aurora-A residue, His187,
is more than 9 Å from the staple. TPX2 residues known to be
crucial for binding to Aurora-A (Trp34 and Phe35) remain in
identical conformations as found in the native TPX2 structure.
By superposing the existing structure of Aurora-A in complex
with native TPX2 (PDB: 1OL5) onto our structure, we were
able to easily visualize the inﬂuence of the hydrocarbon staple
on the binding mode of the stapled TPX2 and its two domains
(Figure 6). The N-terminal extended sequence motif of our
stapled peptide overlays remarkably closely to that of native
TPX2 (RMSD: 0.38 Å) with residues known to be crucial for
binding to Aurora-A in almost identical conformations between
the two structures (Figure 6B and C). This indicates that the
introduction of the staple has no eﬀect on the binding mode
nor conformation of the extended region of TPX2.
The conformation of the α-helical region of TPX2, in
contrast, varies between stapled and native TPX2 structures
(Figure 6A). The staple extends the length of the helix by an
additional turn, and the buried surface area at the interface with
Aurora-A is increased by over 25% (RMSD: 1.63). The ﬁnal
turn is kinked and follows the contour of the surface of Aurora-
A. This ﬂips round the position of TPX2 Glu42, orienting this
side chain toward Aurora-A in the stapled TPX2 structure.
Despite these diﬀerences in the shape and length of the TPX2
helix, the residues on the helix known to be crucial for binding
Figure 6. (A) View of Aurora-A (gray) bound to stapled TPX2 (cyan) with native TPX2 (magenta, PDB: 1OL5) overlaid. TPX2 residues known to
be crucial for binding to Aurora-A are shown as sticks to highlight the conserved binding mode between stapled and native TPX: (B) Tyr8 and
Tyr10, (C) Phe16 and Phe19, (D) Asp11 and Trp34, (E) potential salt bridges can be seen between Glu36TPX2 and Lys250AurA, and (F) Lys38TPX2
and Glu183AurA.
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of TPX2 to Aurora-A, namely Trp34 and Phe35, overlay very
well between stapled and native TPX2 (Figure 6D). In the
context of the stapled TPX2 helix, electron density is clear for
two additional charged side chains, Glu36 and Lys38, unlike in
the native peptide. These side chains contribute to salt-bridge
and/or electrostatic interactions with Aurora-A, which might
explain why the enthalpic contribution of the interaction is
increased (Figure 6E and F). Most of the water molecules at
the interface are conserved between the two structures.
However, in the structure of Aurora-A bound to stapled
TPX2, there is a clearly deﬁned molecule of MES from the
crystallization buﬀer nestled between the C-terminus of the
helix and the Aurora-A surface. In the native TPX2 structure, a
sulfate ion is present instead, but in almost the same position as
the sulfate moiety of the MES molecule (see Supporting
Information, Figure S1). This is likely due to the diﬀerent
crystallization conditions, which both contained 100 mM MES
buﬀer. However, the condition used for the native crystals has
200 mM sulfate, which might therefore be the dominant
binding ligand. Alternatively, the slightly diﬀerent binding mode
of stapled TPX2 may generate a surface that complements that
of MES more than the native TPX2.
From these data, we can infer that the gain in aﬃnity for
interaction with Aurora-A seen with the stapled TPX2 peptide
10 over the native TPX2 peptide 1 is mainly due to more
favorable enthalpic interactions. The data are also in agreement
with the recently reported conformational selection binding
pathway model.34 Remarkably, neither of the two individual
motifs in native or stapled TPX2 have measurable binding
aﬃnity, and yet the interaction is in the low micromolar range
when they are tethered through a linker. We are currently
investigating the basis of this eﬀect using biophysical
approaches.
The genes encoding Aurora-A kinase and its protein partner
TPX2 are frequently coampliﬁed in cancers, and this complex
and both proteins individually have been proposed as targets
for cancer drug discovery. Due to the inherent diﬃculty in
developing selective active site kinase inhibitors, targeting this
protein−protein interaction (PPI) with allosteric small
molecule ligands provides a novel strategy to develop Aurora-
A inhibitors with enhanced selectivity.35−37 Indeed, a recent
study reported a small molecule, an allosteric inhibitor of
Aurora-A, that binds in the hydrophobic pocket between the β
sheetAUR, helix αBAUR, and helix αCAUR and blocks the
interaction with TPX2.38 Similarly, a synthetic single domain
antibody, vNAR-D01, was shown to bind to the same pocket
and inhibit Aurora-A through stabilization of a distorted
conformation of the αC-helix.39 It is very interesting that the
same pocket can be used to positively and negatively regulate
Aurora-A activity, and this opens up exciting avenues of
research to investigate the consequences of manipulating
Aurora-A activity in cancer cells.
In conclusion, as part of our investigations into the allosteric
regulation of Aurora-A kinase, we synthesized and characterized
a conformationally constrained TPX2 proteomimetic spanning
residues 1−43. ITC data revealed that the constrained TPX2
peptide binds Aurora-A with higher aﬃnity than the
corresponding native peptide and mimics the function of
TPX2 in activating Aurora-A’s autophosphorylation. More
generally, this investigation provides further insight into the
thermodynamic eﬀects of preorganizing peptides using
conformational constraints and demonstrates that proteomi-
metics are useful tool compounds for investigating interactions
between intrinsically disordered domains of proteins.
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